[Extensive trial of a monoclonal immunoenzyme test system for the detection of HBsAg in donors and patients].
The enzyme immunoassay system for hepatitis B diagnosis developed on the basis of monoclonal antibodies to hepatitis B virus surface antigen (HBsAg), EIAmca, was demonstrated to detect twice as many antigen-containing donor sera than DHA test, and 9-10 times more than CIEP. By means of EIAmca, HBsAg could be detected in a larger number of patients' sera and in higher dilutions of the sera. This attests to a higher sensitivity of the developed EIAmca system as compared with diagnostic systems of CIEP, DHA test and EIApca.
Sakaian
N N
NN
Elias
E E
EE
Voronov
A V
AV
Popova
A B
AB
Momot
A M
AM
D000911:Antibodies, Monoclonal / Q000302:isolation & purification; D001782:Blood Donors; D005069:Evaluation Studies as Topic; D006386:Hemagglutination Tests; D006509:Hepatitis B / Q000175:diagnosis*; D006514:Hepatitis B Surface Antigens / Q000032:analysis*; D006801:Humans; D007122:Immunoelectrophoresis; D007124:Immunoenzyme Techniques / Q000295:instrumentation
D000911:Antibodies, Monoclonal; D006514:Hepatitis B Surface Antigens
Rasshirennaia aprobatsiia monoklonal'noĭ immunofermentnoĭ test-sistey dlia detektsii HBsAg u donorov i bol'nykh.